The scrutiny stems from the company's first-quarter 2026 financial disclosure on April 29, 2026. During the report, GE HealthCare posted adjusted earnings per share of $0.99 and slashed its full-year guidance to a range of $4.80 to $5.00, down from the previous target of $4.95 to $5.15. Management attributed these struggles to a recall involving a pharmaceutical diagnostics (PDx) supplier and margin declines within the Patient Care Solutions (PCS) segment.
GE HealthCare Faces Securities Probe Following Earnings Miss
Investors who sustained losses following a sharp decline in GE HealthCare Technologies Inc. shares are being invited to join a securities fraud investigation. The Law Offices of Frank R. Cruz is examining whether the company violated federal laws after management lowered its financial guidance and reported production disruptions.
Market reaction was immediate. Shares of GEHC dropped $9.01, or 13.2%, closing at $59.49 on the day of the announcement. Shareholders seeking to participate in the inquiry or recover potential losses are encouraged to contact the Los Angeles-based firm at 310-914-5007 or via their website to discuss their legal standing.
Comments (0)
No comments yet. Be the first!